Error loading player: No playable sources found

64142

Parallel Session 2: Product Quality Testing for Individualized Medicines

Date
June 27, 2023
This product is not available for individual purchase, but it is available as part of the following products:
Thumbnail for CGTP Summit 2023 / Cell and Gene Therapy Products Symposium 2023
The Cell and Gene Therapy Products (CGTP) Symposium: Manufacturing, Quality and Regulatory Considerations enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products…

With the significant progress in the development of individualized medicines, several issues with respect to their routine quality testing have emerged. As a new batch has to be tested for each patient, an extensive set of quality attributes to be analyzed and elaborate testing methods can be a challenge on both number of samples that are needed and the time that is required for testing. The latter is especially true for verifying the sterility of the drug product. As batches for individualized medicines cannot be stocked and the medical needs often require fast treatment of the patients, standard sterility testing can become the limiting factor for the success of an individualized therapy. In addition, it has to be ensured that the assays will function independent of the patient-specific aspects of the final product. 




In this session, we will discuss key challenges and opportunities with respect to product quality testing for Individualized medicines to enable the successful development of such therapies.




Session Speakers:




USP Evolving Position on Use of Rapid Microbial Methods

Huiping Tu, United States Pharmacopeia 




Defining Microbial Control Strategies for Cell-free and Cell-based Individualized ATMP's

Friedrich von Witzingerode, Genentech, a Member of the Roche Group




Delivering Next Generation Cell Therapy Manufacturing Faster without Compromising Quality

Scott Nichols, Kite, A Gilead Company




Additional Panelists:




Elvira Argus, CBER, FDA

Bryan Silvey, A2 Biotherapeutics, Inc. 

Related Products

Thumbnail for Plenary Session 12: Updates in the Regulatory Landscape for Cell & Gene Therapy Products
Plenary Session 12: Updates in the Regulatory Landscape for Cell & Gene Therapy Products
Several cell and gene therapy products have received marketing approval from health authorities and, with that, a more complete picture is now emerging about the regulatory CMC requirements to commercialize these products…
Thumbnail for Keynote Presentation
Keynote Presentation
Gene Therapy Drug Development for Ultra-Rare Disease: Challenges & Opportunities
Thumbnail for Plenary Session 5: Challenges with Incoming Materials - Raw, Starting, Ancillary, etc.
Plenary Session 5: Challenges with Incoming Materials - Raw, Starting, Ancillary, etc.
Raw material selection decisions early in the development of ATMPs are crucial and can impact the final product quality and ultimately patient safety…